The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Aurobindo Pharma USA, Inc. has initiated a Drug Product Recall for the product Nebivolol Tablets 2.5 mg from USA market due to presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.

Nebivolol Tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. To date, Aurobindo has not received any reports of adverse drug events that are confirmed with this recall. Patients who are prescribed Nebivolol should continue taking their medication, as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication.

Nebivolol Tablets 2.5 mg are light blue colored, round shaped, biconvex uncoated tablets debossed with 'L' on one side and '78' on the other side. Aurobindo USA began shipping impacted batches to customers nationwide from June 13, 2024 to November 20, 2024.

NDC Number	Dosage Strength	Package Size	Lot Number	Expiration Date
59651-137-30	2.5 mg	30's HDPE Container	NB0224001A	04/2027
59651-137-30	2.5 mg	30's HDPE Container	NB0224001B	04/2027